These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

216 related items for PubMed ID: 27593183

  • 21. [Preparation of valsartan nanosuspensions and its in vitro dissolution].
    Li F, Song SS, Liu Y, Guo YX, Pan WS, Yang XG.
    Yao Xue Xue Bao; 2013 Aug; 48(8):1312-8. PubMed ID: 24187842
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Enhance the dissolution rate and oral bioavailability of pranlukast by preparing nanosuspensions with high-pressure homogenizing method.
    Wang L, Hao Y, Liu N, Ma M, Yin Z, Zhang X.
    Drug Dev Ind Pharm; 2012 Nov; 38(11):1381-9. PubMed ID: 22300415
    [Abstract] [Full Text] [Related]

  • 24. Fabrication and in vitro/in vivo evaluation of amorphous andrographolide nanosuspensions stabilized by d-α-tocopheryl polyethylene glycol 1000 succinate/sodium lauryl sulfate.
    Qiao H, Chen L, Rui T, Wang J, Chen T, Fu T, Li J, Di L.
    Int J Nanomedicine; 2017 Nov; 12():1033-1046. PubMed ID: 28223797
    [Abstract] [Full Text] [Related]

  • 25. Solution calorimetry as an alternative approach for dissolution testing of nanosuspensions.
    Kayaert P, Li B, Jimidar I, Rombaut P, Ahssini F, Van den Mooter G.
    Eur J Pharm Biopharm; 2010 Nov; 76(3):507-13. PubMed ID: 20887787
    [Abstract] [Full Text] [Related]

  • 26. Elucidating the particle size effect of andrographolide suspensions on their IVIVC performance in oral absorption.
    Yao S, Chen N, Li M, Wang Q, Sun X, Feng X, Chen Y.
    Eur J Pharm Biopharm; 2022 Oct; 179():65-73. PubMed ID: 36058447
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Development of a chemically stable 10-hydroxycamptothecin nanosuspensions.
    Pu X, Sun J, Wang Y, Wang Y, Liu X, Zhang P, Tang X, Pan W, Han J, He Z.
    Int J Pharm; 2009 Sep 08; 379(1):167-73. PubMed ID: 19505545
    [Abstract] [Full Text] [Related]

  • 29. Mechanistic understanding of salt-induced drug encapsulation in nanosuspension via acid-base neutralization as a nanonization platform technology to enhance dissolution rate of pH-dependent poorly water-soluble drugs.
    Van Ngo H, Park C, Tran TTD, Nguyen VH, Lee BJ.
    Eur J Pharm Biopharm; 2020 Sep 08; 154():8-17. PubMed ID: 32634569
    [Abstract] [Full Text] [Related]

  • 30. A simple and low-energy method to prepare loratadine nanosuspensions for oral bioavailability improvement: preparation, characterization, and in vivo evaluation.
    Yang D, Li R, Zhang F, Qin L, Peng F, Jiang S, He H, Lu X, Zhang P.
    Drug Deliv Transl Res; 2020 Feb 08; 10(1):192-201. PubMed ID: 31482518
    [Abstract] [Full Text] [Related]

  • 31. Influence of drug physicochemical properties on absorption of water insoluble drug nanosuspensions.
    Li W, Quan P, Zhang Y, Cheng J, Liu J, Cun D, Xiang R, Fang L.
    Int J Pharm; 2014 Jan 02; 460(1-2):13-23. PubMed ID: 24184036
    [Abstract] [Full Text] [Related]

  • 32. Effect of particle size on oral absorption of carvedilol nanosuspensions: in vitro and in vivo evaluation.
    Liu D, Pan H, He F, Wang X, Li J, Yang X, Pan W.
    Int J Nanomedicine; 2015 Jan 02; 10():6425-34. PubMed ID: 26508852
    [Abstract] [Full Text] [Related]

  • 33. Formulating food protein-stabilized indomethacin nanosuspensions into pellets by fluid-bed coating technology: physical characterization, redispersibility, and dissolution.
    He W, Lu Y, Qi J, Chen L, Yin L, Wu W.
    Int J Nanomedicine; 2013 Jan 02; 8():3119-28. PubMed ID: 23983465
    [Abstract] [Full Text] [Related]

  • 34. Nanosuspensions as delivery system for gambogenic acid: characterization and in vitro/in vivo evaluation.
    Yuan H, Li X, Zhang C, Pan W, Liang Y, Chen Y, Chen W, Liu L, Wang X.
    Drug Deliv; 2016 Oct 02; 23(8):2772-2779. PubMed ID: 26292058
    [Abstract] [Full Text] [Related]

  • 35. Fabrication and characterization of glimepiride nanosuspension by ultrasonication-assisted precipitation for improvement of oral bioavailability and in vitro α-glucosidase inhibition.
    Rahim H, Sadiq A, Khan S, Amin F, Ullah R, Shahat AA, Mahmood HM.
    Int J Nanomedicine; 2019 Oct 02; 14():6287-6296. PubMed ID: 31496686
    [Abstract] [Full Text] [Related]

  • 36. Fabrication of amorphous curcumin nanosuspensions using β-lactoglobulin to enhance solubility, stability, and bioavailability.
    Aditya NP, Yang H, Kim S, Ko S.
    Colloids Surf B Biointerfaces; 2015 Mar 01; 127():114-21. PubMed ID: 25660094
    [Abstract] [Full Text] [Related]

  • 37. Preparation and characterization of amorphous ezetimibe nanosuspensions intended for enhancement of oral bioavailability.
    Thadkala K, Nanam PK, Rambabu B, Sailu C, Aukunuru J.
    Int J Pharm Investig; 2014 Jul 01; 4(3):131-7. PubMed ID: 25126526
    [Abstract] [Full Text] [Related]

  • 38. Study of effect of variables on particle size of telmisartan nanosuspensions using box-Behnken design.
    Rao MR, Bajaj A.
    Drug Res (Stuttg); 2014 Dec 01; 64(12):663-7. PubMed ID: 24549965
    [Abstract] [Full Text] [Related]

  • 39. Chitosan-coated diacerein nanosuspensions as a platform for enhancing bioavailability and lowering side effects: preparation, characterization, and ex vivo/in vivo evaluation.
    Allam AN, Hamdallah SI, Abdallah OY.
    Int J Nanomedicine; 2017 Dec 01; 12():4733-4745. PubMed ID: 28740381
    [Abstract] [Full Text] [Related]

  • 40. Etoposide Amorphous Nanopowder for Improved Oral Bioavailability: Formulation Development, Optimization, in vitro and in vivo Evaluation.
    Wang Y, Wang S, Xu Y, Wang P, Li S, Liu L, Liu M, Jin X.
    Int J Nanomedicine; 2020 Dec 01; 15():7601-7613. PubMed ID: 33116490
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.